Drug Combination Details
| General Information of the Combination (ID: C16500) | |||||
|---|---|---|---|---|---|
| Name | Morin NP Info | + | MST312 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | STAT3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | |||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Combination treatment with morin and telomerase inhibitor MST-312 reduces cancer stem cell traits by targeting STAT3 and telomerase. | |||||